与传统的β -淀粉样蛋白和Tau蛋白生物标志物相比,评估氧化脂素对阿尔茨海默病连续体中认知测量和白质高信号的预测价值。

IF 4.3 2区 医学 Q1 NEUROSCIENCES
Molecular Neurobiology Pub Date : 2025-11-01 Epub Date: 2025-07-16 DOI:10.1007/s12035-025-05185-w
Alireza Shaabanpoor Haghighi, Mahsa Mayeli, Elham Ramezannezhad, Negin Pouroushaninia, Rezvan Barzegar Parizi, Mahtab Nourollahi-Foumeshi, Nasim Idelkhani, Zahra Dadjou, Niloofar Saeedipour, Negar Safaee, Homa Partoandaz, Mahan Shafie, Mohammad Sadeghi, Marjan Falahati
{"title":"与传统的β -淀粉样蛋白和Tau蛋白生物标志物相比,评估氧化脂素对阿尔茨海默病连续体中认知测量和白质高信号的预测价值。","authors":"Alireza Shaabanpoor Haghighi, Mahsa Mayeli, Elham Ramezannezhad, Negin Pouroushaninia, Rezvan Barzegar Parizi, Mahtab Nourollahi-Foumeshi, Nasim Idelkhani, Zahra Dadjou, Niloofar Saeedipour, Negar Safaee, Homa Partoandaz, Mahan Shafie, Mohammad Sadeghi, Marjan Falahati","doi":"10.1007/s12035-025-05185-w","DOIUrl":null,"url":null,"abstract":"<p><p>Oxylipins are signaling molecules that result from the oxidation of long-chain polyunsaturated fatty acids, and they have been attracting attention due to their potential use as biomarkers for the early detection of Alzheimer's disease (AD) and other disorders. In contrast to beta-amyloid and tau protein biomarkers, we aimed to investigate the potential of oxylipins as an AD biomarker to predict cognitive measures. This study analyzed data from 703 participants (mean age 60 years) from the Alzheimer's Disease Neuroimaging Initiative (ADNI). We included 150 cognitively normal (CN) participants, 240 patients with early mild cognitive impairment (EMCI), 145 with late mild cognitive impairment (LMCI), 59 with subjetive memory complaints (SMC), and 109 with AD. Cognitive assessments were conducted using the clinical dementia rating scale (CDR), and cerebrospinal fluid (CSF) biomarkers (Aβ1-42 and p-tau181) were measured via the Luminex platform. Metabolite associations with CSF biomarkers were evaluated using random forest regression and linear regression models, with adjustments for age and sex and normalization for total intracranial volume (tICV). In the random forest regression model, Aβ42 was the most significant predictor for EMCI, while BSH_Sphingosine1P18.2 and BSL_GCDCA were significant for LMCI and MCI, respectively. Aβ42 appeared in SMC and CN but with lower significance than in EMCI. In CN, ASL_ResolvinE2 was most important. BSL_12_HETE was the strongest predictor for AD (R-squared = 0.199, metabolite-CSF R-squared = 0.024). Additionally, BSH_FA20.4_w6 (R-squared = 0.1772) outperformed CSF metabolites in EMCI detection, and BSH_Sphingosine1P16.1 (R-squared = 0.19) outperformed CSF metabolites in LMCI detection. Our findings suggest that select oxylipins may serve as predictive biomarkers of cognitive performance, although conventional CSF biomarkers remain superior for predicting the cognitive findings in the early stages.</p>","PeriodicalId":18762,"journal":{"name":"Molecular Neurobiology","volume":" ","pages":"14156-14166"},"PeriodicalIF":4.3000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluating the Predictive Value of Oxylipins for Cognitive Measures and White Matter Hyperintensities in Alzheimer's Disease Continuum Compared to Conventional Beta‑amyloid and Tau Protein Biomarkers.\",\"authors\":\"Alireza Shaabanpoor Haghighi, Mahsa Mayeli, Elham Ramezannezhad, Negin Pouroushaninia, Rezvan Barzegar Parizi, Mahtab Nourollahi-Foumeshi, Nasim Idelkhani, Zahra Dadjou, Niloofar Saeedipour, Negar Safaee, Homa Partoandaz, Mahan Shafie, Mohammad Sadeghi, Marjan Falahati\",\"doi\":\"10.1007/s12035-025-05185-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Oxylipins are signaling molecules that result from the oxidation of long-chain polyunsaturated fatty acids, and they have been attracting attention due to their potential use as biomarkers for the early detection of Alzheimer's disease (AD) and other disorders. In contrast to beta-amyloid and tau protein biomarkers, we aimed to investigate the potential of oxylipins as an AD biomarker to predict cognitive measures. This study analyzed data from 703 participants (mean age 60 years) from the Alzheimer's Disease Neuroimaging Initiative (ADNI). We included 150 cognitively normal (CN) participants, 240 patients with early mild cognitive impairment (EMCI), 145 with late mild cognitive impairment (LMCI), 59 with subjetive memory complaints (SMC), and 109 with AD. Cognitive assessments were conducted using the clinical dementia rating scale (CDR), and cerebrospinal fluid (CSF) biomarkers (Aβ1-42 and p-tau181) were measured via the Luminex platform. Metabolite associations with CSF biomarkers were evaluated using random forest regression and linear regression models, with adjustments for age and sex and normalization for total intracranial volume (tICV). In the random forest regression model, Aβ42 was the most significant predictor for EMCI, while BSH_Sphingosine1P18.2 and BSL_GCDCA were significant for LMCI and MCI, respectively. Aβ42 appeared in SMC and CN but with lower significance than in EMCI. In CN, ASL_ResolvinE2 was most important. BSL_12_HETE was the strongest predictor for AD (R-squared = 0.199, metabolite-CSF R-squared = 0.024). Additionally, BSH_FA20.4_w6 (R-squared = 0.1772) outperformed CSF metabolites in EMCI detection, and BSH_Sphingosine1P16.1 (R-squared = 0.19) outperformed CSF metabolites in LMCI detection. Our findings suggest that select oxylipins may serve as predictive biomarkers of cognitive performance, although conventional CSF biomarkers remain superior for predicting the cognitive findings in the early stages.</p>\",\"PeriodicalId\":18762,\"journal\":{\"name\":\"Molecular Neurobiology\",\"volume\":\" \",\"pages\":\"14156-14166\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Neurobiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12035-025-05185-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Neurobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12035-025-05185-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

氧化脂素是由长链多不饱和脂肪酸氧化产生的信号分子,由于其作为早期检测阿尔茨海默病(AD)和其他疾病的生物标志物的潜在用途,它们一直备受关注。与β -淀粉样蛋白和tau蛋白生物标志物相比,我们的目的是研究氧化脂素作为AD生物标志物预测认知测量的潜力。这项研究分析了来自阿尔茨海默病神经影像学倡议(ADNI)的703名参与者(平均年龄60岁)的数据。我们纳入了150名认知正常(CN)参与者,240名早期轻度认知障碍(EMCI)患者,145名晚期轻度认知障碍(LMCI)患者,59名主观记忆抱怨(SMC)患者和109名AD患者。使用临床痴呆评定量表(CDR)进行认知评估,并通过Luminex平台测量脑脊液(CSF)生物标志物(Aβ1-42和p-tau181)。使用随机森林回归和线性回归模型评估代谢物与脑脊液生物标志物的关联,调整年龄和性别,并将总颅内容积(tICV)归一化。在随机森林回归模型中,Aβ42是EMCI的最显著预测因子,BSH_Sphingosine1P18.2和BSL_GCDCA分别是LMCI和MCI的显著预测因子。a - β42在SMC和CN中出现,但与EMCI相比,其显著性较低。在CN中,ASL_ResolvinE2是最重要的。BSL_12_HETE是AD的最强预测因子(R-squared = 0.199,代谢物- csf R-squared = 0.024)。此外,BSH_FA20.4_w6 (r²= 0.1772)在EMCI检测中优于脑脊液代谢物,bsh_sphingosinine1p16.1 (r²= 0.19)在LMCI检测中优于脑脊液代谢物。我们的研究结果表明,尽管传统的脑脊液生物标志物在预测早期阶段的认知结果方面仍然优于传统的脑脊液生物标志物,但选择的氧化脂素可以作为认知表现的预测性生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluating the Predictive Value of Oxylipins for Cognitive Measures and White Matter Hyperintensities in Alzheimer's Disease Continuum Compared to Conventional Beta‑amyloid and Tau Protein Biomarkers.

Oxylipins are signaling molecules that result from the oxidation of long-chain polyunsaturated fatty acids, and they have been attracting attention due to their potential use as biomarkers for the early detection of Alzheimer's disease (AD) and other disorders. In contrast to beta-amyloid and tau protein biomarkers, we aimed to investigate the potential of oxylipins as an AD biomarker to predict cognitive measures. This study analyzed data from 703 participants (mean age 60 years) from the Alzheimer's Disease Neuroimaging Initiative (ADNI). We included 150 cognitively normal (CN) participants, 240 patients with early mild cognitive impairment (EMCI), 145 with late mild cognitive impairment (LMCI), 59 with subjetive memory complaints (SMC), and 109 with AD. Cognitive assessments were conducted using the clinical dementia rating scale (CDR), and cerebrospinal fluid (CSF) biomarkers (Aβ1-42 and p-tau181) were measured via the Luminex platform. Metabolite associations with CSF biomarkers were evaluated using random forest regression and linear regression models, with adjustments for age and sex and normalization for total intracranial volume (tICV). In the random forest regression model, Aβ42 was the most significant predictor for EMCI, while BSH_Sphingosine1P18.2 and BSL_GCDCA were significant for LMCI and MCI, respectively. Aβ42 appeared in SMC and CN but with lower significance than in EMCI. In CN, ASL_ResolvinE2 was most important. BSL_12_HETE was the strongest predictor for AD (R-squared = 0.199, metabolite-CSF R-squared = 0.024). Additionally, BSH_FA20.4_w6 (R-squared = 0.1772) outperformed CSF metabolites in EMCI detection, and BSH_Sphingosine1P16.1 (R-squared = 0.19) outperformed CSF metabolites in LMCI detection. Our findings suggest that select oxylipins may serve as predictive biomarkers of cognitive performance, although conventional CSF biomarkers remain superior for predicting the cognitive findings in the early stages.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular Neurobiology
Molecular Neurobiology 医学-神经科学
CiteScore
9.00
自引率
2.00%
发文量
480
审稿时长
1 months
期刊介绍: Molecular Neurobiology is an exciting journal for neuroscientists needing to stay in close touch with progress at the forefront of molecular brain research today. It is an especially important periodical for graduate students and "postdocs," specifically designed to synthesize and critically assess research trends for all neuroscientists hoping to stay active at the cutting edge of this dramatically developing area. This journal has proven to be crucial in departmental libraries, serving as essential reading for every committed neuroscientist who is striving to keep abreast of all rapid developments in a forefront field. Most recent significant advances in experimental and clinical neuroscience have been occurring at the molecular level. Until now, there has been no journal devoted to looking closely at this fragmented literature in a critical, coherent fashion. Each submission is thoroughly analyzed by scientists and clinicians internationally renowned for their special competence in the areas treated.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信